title: Antiangiogenic treatment for multiple CNS hemangioblastomas.
abstract: BACKGROUND
  Hemangioblastomas represent rare benign tumors of the central nervous system. In the case of metastatic spread and limited surgical options, systemic treatment may be considered. However there is no standard of care beyond surgery.
  
  
  METHODS
  We report the cases of 2 patients with progressive multilocular hemangioblastomas, who showed clinical benefit and radiological stabilization of tumor growth after treatment with bevacizumab, an antibody against the vascular endothelial growth factor.
  
  
  CONCLUSIONS
  Our case reports suggest activity of bevacizumab in hemangioblastomas after failure of standard therapeutic options.
authors: Divison of Medical Oncology, Cantonal Hospital of Lucerne, Switzerland. christian.riklin@ksl.ch
authors: Christian
authors: C
authors: Riklin
authors: Katharina
authors: K
authors: Seystahl
authors: Silvia
authors: S
authors: Hofer
authors: Caroline
authors: C
authors: Happold
authors: Ralph
authors: R
authors: Winterhalder
authors: Michael
authors: M
authors: Weller
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D018325:Hemangioblastoma / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab